Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in patients with dyslipidemia

Francesco Di Pierro,1 Pietro Putignano,2 Tarcisio Ferrara,3 Carmela Raiola,4 Giuliana Rapacioli,5 Nicola Villanova6 1Scientific Department, Velleja Research, Milan, Italy; 2Outpatient Diabetic Clinic, University Hospital San Gerardo, Monza, Italy; 3District 63, Cava de’ Tirreni-Costa d&...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Di Pierro F, Putignano P, Ferrara T, Raiola C, Rapacioli G, Villanova N
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	berberine Berberol®K silymarin P-glycoprotein cholesterol triglycerides Monascus purpureus Monakopure™-K20. Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/00dc716845f146ea9f628f35637121aa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:00dc716845f146ea9f628f35637121aa
record_format	dspace
spelling	oai:doaj.org-article:00dc716845f146ea9f628f35637121aa2021-12-02T04:02:55ZRetrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in patients with dyslipidemia1179-1438https://doaj.org/article/00dc716845f146ea9f628f35637121aa2016-12-01T00:00:00Zhttps://www.dovepress.com/retrospective-analysis-of-the-effects-of-a-highly-standardized-mixture-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Francesco Di Pierro,1 Pietro Putignano,2 Tarcisio Ferrara,3 Carmela Raiola,4 Giuliana Rapacioli,5 Nicola Villanova6 1Scientific Department, Velleja Research, Milan, Italy; 2Outpatient Diabetic Clinic, University Hospital San Gerardo, Monza, Italy; 3District 63, Cava de’ Tirreni-Costa d’Amalfi, Salerno, Italy; 4Outpatient Clinic “Ordine di Malta”, Naples, Italy; 5AIOR, Piacenza, Italy; 6Metabolic Disorders, S. Orsola Malpighi Hospital, Bologna, Italy Background: Berberis aristata, because of its berberine content, and Monascus purpureus fermented rice, because of the presence of monacolins (naturally derived statins), are widely investigated food-grade ingredients used to formulate cholesterol-lowering supplements. Although they are extensively used, berberine is poorly absorbed and monacolins are poorly chemically characterized, not standardized, and possibly contaminated with toxic compounds. Silymarin is reported to enhance berberine absorption, while Monakopure™-K20 (MK-20) is a highly standardized red yeast rice containing monacolins K and KA in the ratio of 1:1 but not secondary monacolins, dehydromonacolins, or citrinin.Aim: The effects of a cholesterol-lowering supplement (Berberol®K) containing berberine, silymarin, and MK-20 (BSM) in patients with dyslipidemia were clinically analyzed.Methods: The clinical role of BSM in naïve and in statin-intolerant patients was retrospectively evaluated and the effects observed were compared with those obtained in patients without treatment or treated with lovastatin.Results: Total cholesterol, low density lipoprotein, and triglyceride levels were approximately 4%, 6%, and 11% lower, respectively, and the creatine phosphokinase increase was reduced in patients treated with BSM compared to those treated with lovastatin. Similar results were also obtained in statin-intolerant subjects where BSM was administered as add-on therapy to ezetimibe or fenofibrate. Conclusion: BSM is a food supplement potentially useful 1) as a primary intervention in low-cardiovascular-risk subjects with dyslipidemia; 2) as add-on therapy in mildly statin-intolerant patients; and 3) in dyslipidemic patients with a negative perception of statins who prefer a treatment seen as natural. Keywords: berberine, Berberol®K, silymarin, P-glycoprotein, cholesterol, triglycerides, Monascus purpureus, Monakopure™-K20Di Pierro FPutignano PFerrara TRaiola CRapacioli GVillanova NDove Medical PressarticleberberineBerberol®KsilymarinP-glycoproteincholesteroltriglyceridesMonascus purpureusMonakopure™-K20.Therapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 9, Pp 1-7 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	berberine Berberol®K silymarin P-glycoprotein cholesterol triglycerides Monascus purpureus Monakopure™-K20. Therapeutics. Pharmacology RM1-950
spellingShingle	berberine Berberol®K silymarin P-glycoprotein cholesterol triglycerides Monascus purpureus Monakopure™-K20. Therapeutics. Pharmacology RM1-950 Di Pierro F Putignano P Ferrara T Raiola C Rapacioli G Villanova N Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in patients with dyslipidemia
description	Francesco Di Pierro,1 Pietro Putignano,2 Tarcisio Ferrara,3 Carmela Raiola,4 Giuliana Rapacioli,5 Nicola Villanova6 1Scientific Department, Velleja Research, Milan, Italy; 2Outpatient Diabetic Clinic, University Hospital San Gerardo, Monza, Italy; 3District 63, Cava de’ Tirreni-Costa d’Amalfi, Salerno, Italy; 4Outpatient Clinic “Ordine di Malta”, Naples, Italy; 5AIOR, Piacenza, Italy; 6Metabolic Disorders, S. Orsola Malpighi Hospital, Bologna, Italy Background: Berberis aristata, because of its berberine content, and Monascus purpureus fermented rice, because of the presence of monacolins (naturally derived statins), are widely investigated food-grade ingredients used to formulate cholesterol-lowering supplements. Although they are extensively used, berberine is poorly absorbed and monacolins are poorly chemically characterized, not standardized, and possibly contaminated with toxic compounds. Silymarin is reported to enhance berberine absorption, while Monakopure™-K20 (MK-20) is a highly standardized red yeast rice containing monacolins K and KA in the ratio of 1:1 but not secondary monacolins, dehydromonacolins, or citrinin.Aim: The effects of a cholesterol-lowering supplement (Berberol®K) containing berberine, silymarin, and MK-20 (BSM) in patients with dyslipidemia were clinically analyzed.Methods: The clinical role of BSM in naïve and in statin-intolerant patients was retrospectively evaluated and the effects observed were compared with those obtained in patients without treatment or treated with lovastatin.Results: Total cholesterol, low density lipoprotein, and triglyceride levels were approximately 4%, 6%, and 11% lower, respectively, and the creatine phosphokinase increase was reduced in patients treated with BSM compared to those treated with lovastatin. Similar results were also obtained in statin-intolerant subjects where BSM was administered as add-on therapy to ezetimibe or fenofibrate. Conclusion: BSM is a food supplement potentially useful 1) as a primary intervention in low-cardiovascular-risk subjects with dyslipidemia; 2) as add-on therapy in mildly statin-intolerant patients; and 3) in dyslipidemic patients with a negative perception of statins who prefer a treatment seen as natural. Keywords: berberine, Berberol®K, silymarin, P-glycoprotein, cholesterol, triglycerides, Monascus purpureus, Monakopure™-K20
format	article
author	Di Pierro F Putignano P Ferrara T Raiola C Rapacioli G Villanova N
author_facet	Di Pierro F Putignano P Ferrara T Raiola C Rapacioli G Villanova N
author_sort	Di Pierro F
title	Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in patients with dyslipidemia
title_short	Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in patients with dyslipidemia
title_full	Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in patients with dyslipidemia
title_fullStr	Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in patients with dyslipidemia
title_full_unstemmed	Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in patients with dyslipidemia
title_sort	retrospective analysis of the effects of a highly standardized mixture of berberis aristata, silybum marianum, and monacolins k and ka in patients with dyslipidemia
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/00dc716845f146ea9f628f35637121aa
work_keys_str_mv	AT dipierrof retrospectiveanalysisoftheeffectsofahighlystandardizedmixtureofberberisaristatasilybummarianumandmonacolinskandkainpatientswithdyslipidemia AT putignanop retrospectiveanalysisoftheeffectsofahighlystandardizedmixtureofberberisaristatasilybummarianumandmonacolinskandkainpatientswithdyslipidemia AT ferrarat retrospectiveanalysisoftheeffectsofahighlystandardizedmixtureofberberisaristatasilybummarianumandmonacolinskandkainpatientswithdyslipidemia AT raiolac retrospectiveanalysisoftheeffectsofahighlystandardizedmixtureofberberisaristatasilybummarianumandmonacolinskandkainpatientswithdyslipidemia AT rapaciolig retrospectiveanalysisoftheeffectsofahighlystandardizedmixtureofberberisaristatasilybummarianumandmonacolinskandkainpatientswithdyslipidemia AT villanovan retrospectiveanalysisoftheeffectsofahighlystandardizedmixtureofberberisaristatasilybummarianumandmonacolinskandkainpatientswithdyslipidemia
_version_	1718401408554762240

Retrospective analysis of the effects of a highly standardized mixture of Berberis aristata, Silybum marianum, and monacolins K and KA in patients with dyslipidemia

Ejemplares similares